evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

2,447 questions · 2,590 findings · 266 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 699 · 27%GRADE not reported 289 · 11.2%Very low 614 · 23.7%Low 605 · 23.4%Moderate 322 · 12.4%High 61 · 2.4%

Low molecular weight heparin vs active control

Symptomatic PE · ambulatory cancer patients receiving chemotherapy

Low‐molecular‐weight heparin showed no clear difference in symptomatic PE compared with with active control (1); GRADE not reported.

3 findings from 1 review

Low molecular weight heparin vs active control

Symptomatic DVT · ambulatory cancer patients receiving chemotherapy

The review found no eligible studies for this question.

3 findings from 1 review

Low molecular weight heparin vs active control

Total VTE · ambulatory cancer patients receiving chemotherapy

Low‐molecular‐weight heparin showed no clear difference in any VTE compared with with active control (1); GRADE not reported.

3 findings from 1 review

Low molecular weight heparin vs active control

1‐year overall mortality · ambulatory cancer patients receiving chemotherapy

The review found no eligible studies for this question.

3 findings from 1 review

Low molecular weight heparin vs active control

Clinically relevant bleeding · ambulatory cancer patients receiving chemotherapy

The review found no eligible studies for this question.

3 findings from 1 review

tDCS vs active control

Secondary outcome measure: lower extremity function at the end of · people with stroke
2 findings from 1 review

tDCS vs active control

Muscle strength · people with stroke
2 findings from 1 review

tDCS vs active control

Secondary outcome measure: cognitive abilities at the end of · people with stroke

The review found no eligible studies for this question.

2 findings from 1 review

tDCS vs active control

Dropouts, adverse events and deaths during intervention phase Numbers of dropouts, adverse events and deaths from all causes · people with stroke

tDCS showed no clear difference in secondary outcome measure: dropouts, adverse events and deaths… compared with any type of active control intervention (moderate certainty).

1 finding from 1 review

tDCS vs active control

ADL outcome · people with stroke

The review found no eligible studies for this question.

2 findings from 1 review

tDCS vs active control

Secondary outcome measure: mean upper extremity function at the end of the intervention periodClinical measures of upper extremity function. Scale from: 0 to infinity. · people with stroke
2 findings from 1 review